AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01011699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: After 6 months of treatment, patient screening on PTH level:~For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.
Study NCT04311190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family engagement
Description: Physical exercises and simple care tasks
Study NCT01727206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study NCT02806505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
Study NCT04387045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guilty feelings
Description: Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
Study NCT04387045 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guilty feelings
Description: Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
Study NCT02377323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MACFIMS
Description: Cognitive evaluation of 50 participants
Study NCT02377323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MSQoL-54
Description: Quality of life questionnaires
Study NCT01826045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-gamma Glutamic Acid
Study NCT01826045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03142256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentivised - Conditional Cash Transfer
Description: Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
Study NCT03142256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada 200Mg-300Mg Tablet
Description: Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
Study NCT02372942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lattoferrin
Description: 515 pregnant women using lattoferrin to prevent preterm delivery
Study NCT02372942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
Study NCT00549471 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: physiotherapy
Description: CG children will undergo a program of intensive physiotherapy
Study NCT00549471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A and physiotherapy
Description: BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
Study NCT05849792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and psychological intervention
Description: Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive.
Study NCT02679456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Study NCT02679456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study NCT04118777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
Study NCT04118777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
Study NCT02087137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory and Aging Program
Study NCT03089853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
Study NCT02397343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperbaric oxygen
Study NCT01181609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
Study NCT02330276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
Study NCT02619526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 10mg, once a day
Study NCT02619526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 25mg, twice a day
Study NCT01509443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
Study NCT03837483 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-103
Description: Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
Study NCT02450890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First, then ORADUR®
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
Study NCT02450890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORADUR® First, then Placebo
Description: ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
Study NCT04596605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2309
Description: Food for Special Medical Purpose / 4 capsules daily for 12 weeks
Study NCT05061433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support
Description: MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
Study NCT02087943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Orally twice a day (BID)
Study NCT02087943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally twice a day (BID)
Study NCT02087943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally twice a day (BID)
Study NCT04596605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: 2 capsules daily for 12 weeks
Study NCT04171245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughie laughter prescription
Description: Creation of a Laughie; laughing with their Laughie 3x a day
Study NCT04171245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep tracking equipment
Description: Tracking sleep using equipment
Study NCT04171245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep tracking equipment
Description: Tracking sleep using equipment
Study NCT01200277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebroplasty
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
Study NCT01200277 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
Study NCT03394625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket shield technique
Description: Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
Study NCT03394625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using Xenograft material
Description: placing xenograft material in gap between the implant and the buccal plate of bone
Study NCT04008485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Electric Impedance Spectroscopy Device to predict PTB
Description: During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
Study NCT01438931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-9501
Description: Dexmedetomidine hydrochloride variable dose
Study NCT01438931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03666949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: All General anesthesia
Description: Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation
Study NCT03666949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: All Locoregional anesthesia
Description: Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block
Study NCT02772146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS UF
Description: One single ultrafiltration session of 10 hours.
Study NCT00703118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
Study NCT00703118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN-alfa-2a
Description: Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
Study NCT00703118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
Study NCT00703118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
Study NCT02204098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mammaglobin-A DNA Vaccine
Study NCT03006263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Laparoscopic Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study NCT02204098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optional biopsy
Study NCT02204098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional biopsy
Study NCT03006263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study NCT01519973 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SPECT/CT processed with Evolution for CardiacTM software
Description: SPECT/CT to be compared with PET/CT
Study NCT02756364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant IM injection.
Study NCT02756364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.
Study NCT02727257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
Study NCT00097838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen
Study NCT02756364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsule.
Study NCT03593187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cal-1 (LVsh5/C46) drug product
Description: Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
Study NCT04677452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR129
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
Study NCT00530790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole controlled release (CR)-RLS
Description: White film-coated round-shaped tablet
Study NCT01842906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theravent
Description: nasal EPAP device
Study NCT01842906 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham device without EPAP
Study NCT02650700 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: spleen radiotherapy
Description: Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
Study NCT02650700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spleen radiotherapy
Description: Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
Study NCT02005900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
Description: Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
Study NCT01399489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
Study NCT03970200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 001
Description: Fecal Microbiota for Transplant, enema product
Study NCT03970200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 002
Description: Fecal Microbiota for Transplant, suspension product
Study NCT03970200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 003
Description: Fecal Microbiota for Transplant, capsule product
Study NCT03970200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Standard of care antibiotics
Study NCT03970200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Standard of care antibiotics
Study NCT03433859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
Study NCT03433859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Aluminium Chloride (cosmetic product)
Description: Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
Study NCT04084899 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure therapy
Description: Standard treatment with continuous positive airway pressure
Study NCT01335854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Access to CPAP Data
Description: Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.